Article

Wal-Mart recognizes lens manufacturer

Vision-Ease Lens Inc., a manufacturer of polycarbonate ophthalmic lenses, earned the designation of Wal-Mart's Specialty Supplier of the quarter.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
Related Content
(Image credit: Wilmer Eye Institute/Johns Hopkins Medicine)
June 27th 2025

Wilmer Eye Institute marks 100 years: honoring the past, shaping the future

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Krystal Biotech doses first patient in phase 3 trial IOLITE
June 27th 2025

Krystal Biotech doses first patient in phase 3 trial IOLITE

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Aldeyra Therapeutics receives Special Protocol Assessment Agreement Letter from FDA for ADX-2191
June 26th 2025

Aldeyra Therapeutics receives Special Protocol Assessment Agreement Letter from FDA for ADX-2191

36-month results from phase 1/2a clinical study of RG6501 released
June 26th 2025

36-month results from phase 1/2a clinical study of RG6501 released

© 2025 MJH Life Sciences

All rights reserved.